Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces positive topline results of data from its Phase III clinical trial (NCT05438407) evaluating the ...

Through a recent notice, the Medical Assessment and Rating Board (MARB) of the National Medical Commission (NMC) has invited ...